When introduced by German pharmaceutical manufacturer Boehringer Ingelheim, it was hoped the prescription drug Pradaxa would replace Coumadin, a popular blood-thinning product with a troubled history of serious side effects. Both drugs are prescribed to reduce the risk of stroke in patients with irregular heart rhythms. Unfortunately, however, hopes for Pradaxa as a replacement for Coumadin did not come to fruition.
According to the Food and Drug Administration (FDA), over 1.1 million prescriptions for Pradaxa (dabigatran), were filled between October 2010 and October 2011. However, in 2011 alone, the FDA received reports of around 3,700 adverse drug reactions to Pradaxa. More than 500 deaths were reportedly linked to it.
Approved for sale by the FDA in October 2010 and still on the market, Pradaxa is now the focus of large scale litigation.
As experienced personal injury attorneys in Chicago, our firm helps clients pursue their rights after injury caused by Pradaxa. In recent legal news, the Joint Panel on Multidistrict Litigation (JPML) entered an order consolidating current and future federally-filed Pradaxa cases in the Southern District of Illinois. In reviewing 21 federal cases, the JPML held that:
- The actions concern common questions of fact
- Centralization in Illinois serves both parties and witnesses
- The actions share common allegations of severe bleeding caused by irreversible effects of the anticoagulant Pradaxa
- Consolidation avoids duplicate discovery, and preserves the resources of both the parties and the judiciary
Our Chicago personal injury attorneys represent individuals and families injured by Pradaxa. If you have questions, contact our office about your injury.